header logo image


Page 35«..1020..34353637..40..»

Archive for March, 2020

Fitness: It’s never too soon to embrace positive aging – Montreal Gazette

Monday, March 9th, 2020

As an increasing number of Canadians enter their middle and golden years, theres less talk of finding the fountain of youth and more discussion around positive aging. This shift in thinking is a welcome change from trying to turn back the clock, moving toward the more attainable goal of maintaining a high quality of life into retirement.

Its not just boomers and Gen Xers who are hoping to redefine what it means to age. Governments and municipalities understand that a healthy community of older adults puts less strain on public resources, which means they have a vested interest in keeping their aging citizens active and healthy. And given that First World millennials and the generations that follow are expected to live to 100, its more important than ever to pursue a lifestyle devoted to healthy aging.

Philip Pizzo from the departments of pediatrics and microbiology/immunology at Stanford University penned an editorial in the Journal of the American Medical Association titled A Prescription for Longevity in the 21st Century. His goal isnt just to add years to ones life, but to make the later decades of life more meaningful and functional and less attenuated to the morbidities that lead to medical, social and financial dependency. In other words, hes touting the benefits of maintaining a healthy body, social life and bank account as the decades add up.

It seems obvious that Pizzos prescription for longevity is directed at those in their middle years and beyond, but investing in longevity early will increase the odds of reaping the rewards from living a vibrant and purposeful life. So dont wait until retirement looms to pursue the following life goals its never too early to embrace positive aging.

Individuals with a university education have a greater life expectancy than those without. Low levels of education often result in lower income; according to American data, this results in a greater tendency toward declining physical and mental health, as well as an increase in unemployment. Statistics suggest a 15-year difference in life expectancy between the richest and poorest Americans.

Urging the youngest generations to stay in school has been a common refrain, but catching up on missed education and the opportunities it offers never gets old. Lifelong learning isnt just a stepping stone to good fiscal health its an important investment in living longer.

Having a purpose beyond oneself like caring for others, improving the world around you, sharing your expertise, getting involved in community groups and following a spiritual path translates into a longer life, according to studies of the young and old. Starting each day with a sense of purpose and a commitment to contributing to society is like a daily dose of medicine.

With age comes more time to give of yourself, so the idea of creating opportunities for senior members of the community to share their experience and knowledge benefits society as a whole. While retirement is often viewed as the end of your value, its actually an opportunity to give more to society than you get back.

Social connection is associated with a 50 per cent boost in survival. Loneliness, on the other hand, can lead to increased risk of cardiovascular disease and stroke. To put it more simply, having friends is good for your health.

Prioritizing relationships and staying engaged with family, friends, neighbours and co-workers is key to maintaining a high level of connectedness. Yet there are plenty of times when isolation is common, including changing schools, jobs or cities; separation from a spouse, partner or other family members; and retirement. Maintaining varied social networks allows for support during periods of change and reduces the risk of isolation.

Its well known that exercising regularly, getting enough sleep and eating nutritious food improves health, well-being and longevity. Whats less understood is that adopting a healthy lifestyle is one of the only proven ways to reduce genetic risk factors like heart disease, obesity and mental illness.

Building healthy habits early also means enjoying the resulting energy, strength and positive mood on either side of middle age. But the real payback comes during those years when age begins to whittle away at the physical and mental competencies we take for granted in youth. Putting a priority on exercising, eating well and getting enough sleep slows down the physical decline, and is good for both mind and body.

Read more here:
Fitness: It's never too soon to embrace positive aging - Montreal Gazette

Read More...

Which is really the weaker sex? – The Economist

Monday, March 9th, 2020

It depends on the way sex is determined in the first place

Mar 7th 2020

WOMEN LIVE longer than men. And, more generally, female mammals live longer than male ones. This might be put down to the fact that males live more dangerous lives than femalescompetition for the affections of those females being an ingrained part of malehood. Such competition leads either to dangerous fights, or to the growing of showy-offy but physiologically expensive and thus life-limiting accoutrements, or both. All of which would make perfect sense were it not also true that male birds, which cede nothing to their mammalian counterparts in the fighting and showing-off departments, nevertheless manage, on average, to outlive their respective females. Male spruce grouse (pictured), for example, live for 13 years; females for five.

A long-standing hypothesis holds the sex chromosomes to blame. Male mammals are, in the jargon, heterogametic. They have X and Y chromosomes, whereas females have a pair of Xs. In birds, it is the females which are heterogametic. In both groups, the sex-determining chromosome is a stubby thing that is missing many of the genes on its counterpart. It therefore cannot cover for its partners genetic deficiencies by providing working copies of genes which are mutated in that partner. (In humans, haemophilia, Duchenne muscular dystrophy and colour-blindness are all caused this way.) As a result, the heterogametic sex is less resilient and dies earlier.

It is a plausible idea. But two sample points (mammals and birds) do not prove it. So Zoe Xirocostas and her colleagues at the University of New South Wales, in Sydney, Australia have looked further. As they describe in Biology Letters, they searched the literature for animals where both the relative longevity of the sexes and the nature of any heterogameticity are known.

Adding reptiles, amphibians, sharks, bony fish, arachnids and insects to the list, they confirmed that the relationship between longevity and heterogameticity does indeed hold up in other groups of animals. But there is a twist. When males are heterogametic the sex difference in lifespan averages 20.9%. Despite extreme examples like the spruce grouse, however, when females are heterogametic the average difference is only 7.1%. These numbers suggest that fighting and showing off are involved in determining longevity differences, too.

This article appeared in the Science and technology section of the print edition under the headline "Which is really the weaker sex?"

Visit link:
Which is really the weaker sex? - The Economist

Read More...

Shortcuts We Love – The New York Times

Monday, March 9th, 2020

Welcome to Five Weeknight Dishes, where each Friday we present five different answers to the eternal question: Whats for dinner? Depending on the distractions of any given day, this question penetrates my consciousness some time between 12 and 6 p.m. The hour helps determine the answer and how much time I have to cook.

This has been an exceptionally distracting week, so Ive been looking for last-minute dishes with quick-cooking shortcuts like frozen puff pastry, boneless chicken breasts, and canned beans: ingredients that I tend to keep on hand anyway. Making dinner is an excellent way to keep your mind off current events, if only for half an hour. (As a soundtrack, try out a food podcast like The Splendid Table or the tireless Kitchen Sisters instead of the news.)

[Sign up here to receive the Five Weeknight Dishes newsletter in your inbox every Friday.]

Here are this weeks recipes:

1. Longevity Noodles With Chicken, Ginger and Mushrooms

This is a wonderfully basic recipe stir-fried noodles with protein, vegetables and a few aromatics that functions as a complete meal. Swap in other quick-cooking greens, replace the chicken with tofu, or leave it out altogether and top with sunny-side-up eggs and a drizzle of soy sauce and chile oil.

2. Vegan Caesar Salad With Crisp Chickpeas

Its the umami-rich seasonings of Caesar salad usually some combination of Worcestershire sauce, anchovies and Parmesan that make it so satisfying. Fortunately, garlic, miso paste and nutritional yeast are also packed with umami, but derive from plants making this edit of the classic totally vegan.

View this recipe.

_____

3. Potato Tart With Goat Cheese and Thyme

Three things that I usually stock, but had never put together before this week: puff pastry, goat cheese and potatoes. With thyme leaves, what sounds like a stodgy combination becomes fresh and lively. Make sure to assemble this right before baking, so the bottom crust wont soak up moisture from the cheese.

4. White Beans au Vin

Red wine has complex flavors that make it work really well as a cooking medium, as in coq au vin or beef Bourguignon. Skip rinsing the canned beans and add them directly to the pot the starch thats already in the canning liquid gives the sauce body and softens the edge of the wine.

View this recipe.

_____

See the original post:
Shortcuts We Love - The New York Times

Read More...

Lakers’ LeBron James earns raves from Giannis Antetokounmpo: ‘Makes me want to be there one day’ – CBS Sports

Monday, March 9th, 2020

You can count reigning NBA MVP Giannis Antetokounmpo among those that are extremely impressed with how well Los Angeles Lakers superstar forward LeBron James is playing in his 17th season in the NBA. On the season, James, 35, is averaging 25.4 points, 7.8 rebounds, and a league-leading 10.7 assists per game. His play has propelled the Lakers to the top of the standings in the Western Conference, and has also made him Antetokounmpo's chief competition for this season's MVP Award.

"It's amazing. He's 35 and playing at a high level," Antetokounmpo said of James, ahead of the second meeting of the season between the Bucks and Lakers on Friday. "He just leads the path for us. A lot of times we think that, 'OK, we're going to retire at 35,' but seeing a guy at 35, being still top-three best player in the world, that makes us want to be there. Makes me want to be there one day, so I've got to keep taking care of my body, eating the right way, being healthy, and as I said -- he paved the way, and hopefully we can just follow."

James has redefined what late career success can look like, and younger players like Antetokounmpo have clearly taken note of James' blueprint, which includes remaining in tip-top physical shape at all times, and going the extra mile (or 10) in order to do so. While James is one-of-a-kind, Antetokounmpo certainly has the drive and determination to build a similarly long and productive career. Hopefully he can have similar good fortune when it comes to avoiding major injury issues also, as that has also been crucial to James' longevity.

One thing that has helped James to survive the test of time is his willingness to work on and improve various areas of his game. People used to question his ability to space the floor and now he pulls up from just inside halfcourt with ease. Antetokounmpo shows a similar eagerness to improve. Shortly after he won the MVP Award, Antetokounmpo admitted that there was still plenty of room for improvement in his game. In fact, he went as far as to say that he thought he had only reached 60 percent of his potential as a player.

"There's a lot of things I can improve on," Antetokounmpo said. "First of all, [I have to] look at myself before I look at anybody else. Try to self-improve as much as possible. There are a lot of things that I got to work on in my game... A lot of people say, 'You are the MVP, you are one of the best players in the league, you are so dominant. But I think I can get better. I think I am at 60 percent of my potential, as good as I can be. I just want to be better, react better, play the game better, play better, execute better."

It's not too often that you hear an MVP candidate openly admit to being amazed by another candidate's production, but James is an exception. Considering how long he's been at it, all of the players in the league today are impressed by how dominant he still is, even ones as good as Antetokounmpo. James has raised the bar, and inspired his peers in the process.

Visit link:
Lakers' LeBron James earns raves from Giannis Antetokounmpo: 'Makes me want to be there one day' - CBS Sports

Read More...

When will Thatcher’s death die? – i-D

Monday, March 9th, 2020

At the time of writing, the website IsThatcherDeadYet.co.uk has been live for almost ten years. Its original "NOT YET" has long been replaced with an affirmative "YES". Nonetheless, it remains active, just in case you need reminding.

A dedicated website appears quaint now, but when former Tory Prime Minister Margaret Thatcher died in 2013 the internet served as the coordinator for real-world festivities. Impromptu street parties were organised over social media, attracting hundreds at a time and thanks to a Facebook campaign, "Ding Dong! The Witch is Dead" from The Wizard of Oz film famously peaked at number two in the charts -- earning itself the Wikipedia subheading of usage as a meme in politics.

At the time the meme may have seemed like a flash in the pan joke. Few in 2013 could have predicted its longevity and the impact to come. In the seven years since, the death of Margaret Thatcher has resurfaced intermittently in online discourse as a perennial trump card in the arsenal of online British leftists, a morale booster for trying times, or an example of the internet's particular style of gallows humour.

As it turns out, being a dead old woman who wrecked a nation makes you very versatile meme fodder. Thatcher posthumously partakes in the Dolly Parton challenge -- as a pile of ashes. Her conclusive lack of pulse gets a shout out on TikTok. When the Conservatives commemorated the anniversary of her leadership on social media last month, their tweet was almost instantly ratioed to fuck. Many took the chance to find variations on what or who could be superimposed onto her grave, preferably dancing.

But given that she went to her grave in 2013, why is this particular joke one that endures? Some argue that this particular strain of content exists and thrives as a reaction to the bleak, post-Brexit, tenth consecutive year of Tory Britain; a bitter protest against a country that seems to love nothing more than tasting the boot. Meme contributor Ciaran summarises its well-established attitude: "Shes vermin who destroyed the lives of millions. She deserves all the disrespect she gets.

The country's most recent Conservative election win has only boosted the joke's popularity (not coincidentally, its scale has been compared to the 1987 election where Thatcher first triumphed). When Twitter account Maggies Still Dead ended a two-year hiatus, on New Years Eve, to remind us that Margaret Thatcher spent just 22.7% of this decade breathing, it felt like an act of healing, albeit a particularly brutal one, after a depressing month in British politics.

Users create political memes as a coping mechanism, says Dr. Anastasia Denisova, a lecturer at the University of Westminster and author of Internet Memes of Society. She believes this is particularly potent when it comes to Thatcher discourse. [Margaret Thatcher] symbolises something bigger than herself," Anastasia says. "An era, a political approach, and the tension that arose in response to that."

It's Thatcher's legacy which plays an especially important role in the popularity of these memes, particularly as many of those who create, share or like memes about the politician's death were born after her premiership ended. Amelia, a young Labour activist who has created Thatcher death memes before, says she thinks people her age feel its generational impact from their parents. For a lot of us, disliking Thatcher is the logical conclusion," she says. "Two generations of hurt can be traced back. Thats not easy to forgive. You can dispute whatever claims they make regarding current, living left-wingers; you cant dispute the fact Margaret Thatcher is dead and buried."

Dr Denisova agrees. "As [young people] hold a definitive strong view about her, they find it more legitimate to use her image as a symbol of political vices."

While young people may not have experienced life under Thatcher first hand, we're all too aware of its after-effects, despite what mainstream narratives about the 'ignorant youth' would have people believe. Look no further than to Harry Styless 2013 tribute to the politician which launched a fair few thinkpiece mentions, to see that. However, the assumption of ignorance has persisted, with some factual accuracy. In a 2019 YouGov survey 40% of 18-24 year olds selected "dont know" when asked whether Thatcher had had a positive or negative impact on the UK. Later generations have also subsumed and grown to worship much of the individualist "pull yourself up by your bootstraps" ideology the ex-PM championed -- even though they are more likely to be at its mercy. It makes sense to look for answers, and for disaffected 90s and 00s babies, Thatcher is ground zero: embodying a cultural shift in which they did not partake but is nonetheless their reality.

The ongoing phenomenon, however, is cross-generational too, and it's fuelled by older influencers who do have personal memories of the Thatcher era. Comedian and internet icon Limmy has been a persistent contributor to the anti-Thatcher content factory and has played a significant role in its maintenance -- drawing a man shagging Thatchers grave long before the dancing hotdog got a look in.

Against a backdrop of ludicrous jokes and drawings like Limmy's, Thatcher's death has become an abstract concept, a crude representation of political and societal hope that is frequently crushed. For the young UK left, it acts as an "OK Boomer"-style response to the absurdities of living in the reactionary culture she influenced.

There is also a determination behind the irreverence, anticipating that Thatchers literal end may finally lead to the death of her philosophy. This desire has been at the forefront of the Labour Party since Jeremy Corbyns rise, and its post-election crisis has made it an even more prominent issue. Left-wing Labour MP Zarah Sultanas now-famous maiden speech to the Commons prioritised her aspirations towards ending 40 years of Thatcherism. Even moderates are taking notice, as with leadership candidate Lisa Nandys criticism of New Labour keeping the consensus that Thatcher built.

As the mainstream left concede to the nations distaste for neoliberalism, the opposition seems to be recognising it too. It has been speculated that Boris Johnson may reverse some of the Tories more rampant Thatcherite tendencies, having been grudgingly voted back in by many of the northern constituencies that they devastated. His upcoming budget is expected to massively boost public spending -- coming not long after the announcement that Northern Rail will be renationalised, following years of poor service and complaints.

All of this puts every provocative shitposter in an awkward position. In some ways, it proves their point. The very government that they despise is at face value attempting to validate if not them, then older voters for whom Thatcher is a dirty word. After all, as Ciaran says, She will always be on the wrong side of history.

The meme-ification of Thatchers death, then, is a gleeful negation of her legacy, one which although ludicrous and drawing accusations of bad taste, is arguably part of the movement leading to real life political change. But on a more simple level, it's just an accessible form of protest in a decade that so far has conceded to Toryism. Its morbid reminder brings a welcome certainty the left is not currently afforded. No one has put the final nail in the coffin of conservatism so far, because it hasnt appeared yet. Until then, death is perhaps the only certainty in our uncertain political times.

Go here to read the rest:
When will Thatcher's death die? - i-D

Read More...

Customization to play huge role in funds of tomorrow – Pensions & Investments

Monday, March 9th, 2020

It's not exactly simple to provide tailored advice or information to the millions of participants in U.S. defined contribution plans. But with advancements in technology, new legislation and a retirement community striving to get people to sock more money away for their retirements, industry sources say retirement plans of the future in the U.S. will be shaped by customization.

"In accumulation, particularly the early years, a one-size target-date fund is pretty good for most people, but as you get closer to retirement and into retirement, individual circumstances and needs and wants and financial situation change," said Josh Cohen, Chicago-based head of institutional defined contribution at PGIM Inc., the investment management businesses of Prudential Financial.

Participants would benefit from learning whether they're on track to meet their particular retirement goals and hear what they need to do in order to make those goals a reality, Mr. Cohen said.

Advancements in record-keeper platform capabilities that are now able to "seamlessly pull and protect participant data" make further personalization possible for participants, according to Holly Verdeyen, Chicago-based director of defined contribution investments at Russell Investments.

"There's always been this realization that participant needs are highly personal, especially near retirement, but we just haven't had the ability to deliver that type of individualized advice to people on a mass scale, and now with the advancements in technology we're able to do that better than ever before," Ms. Verdeyen said.

Lew Minsky, Palm Beach Gardens, Fla.-based president and CEO of the Defined Contribution Institutional Investment Association, said customization will grow more prevalent in the coming years and thinks blockchain technology could play a major role. Last fall, DCIIA and the SPARK Institute, which represents retirement industry players such as record keepers, investment advisers, mutual fund companies and benefit consulting firms, held a forum on blockchain technology for the U.S. retirement system.

"We're still early days but you could definitely see an environment where, for example, there is a chain across the industry that has everybody's individual records on it and so all the information necessary for a pretty granular level of customization is available," Mr. Minsky said. "And it would just be about determining which providers within the chain needed what levels of information to be able to facilitate that customization."

And if getting people to save more and smarter is one part of the equation, getting them to save at all is the other. Recent federal and state legislation has opened the door for open multiple employer plans and state-sponsored automatic individual retirement account programs that are known as Secure Choice programs.

Industry stakeholders are confident these types of initiatives will help close the U.S. retirement savings gap. And in Washington, lawmakers are looking to build on the achievements of the Setting Every Community Up for Retirement Enhancement Act, the first retirement security package passed in more than a decade.

Rep. Richard Neal, D-Mass., chairman of the Ways and Means Committee, told Pensions & Investments after the SECURE Act passed in late December that he's working on legislation that will "essentially be the SECURE Act 2.0" and is aiming to move the Automatic Retirement Plan Act and the Retirement Plan Simplification and Enhancement Act with that package.

Mr. Neal in 2017 had introduced the Automatic Retirement Plan Act, which would require many employers to offer a 401(k) or 403(b) plan, and the Retirement Plan Simplification and Enhancement Act, which among other provisions, would exempt retirement savings below $250,000 from complicated required minimum distribution rules. He has yet to do so this Congress.

Link:
Customization to play huge role in funds of tomorrow - Pensions & Investments

Read More...

How to boost your immune system to avoid colds and coronavirus – The Guardian

Monday, March 9th, 2020

Its been a long, wet winter. Everybody has got colds, and now we are braced for a coronavirus epidemic. Boosting our immune system has rarely felt more urgent, but, beyond eating more tangerines and hoping for the best, what else can we do?

Sheena Cruickshank, a professor of immunology at the University of Manchester, has a shocking cold when we speak at a safe distance, over the phone. To know how to take care of your immune system, she says, first you need to understand the weapons in your armoury a cheeringly impressive collection, it turns out.

When you come into contact with a germ youve never met before, she says, youve got various barriers to try to stop it getting into your body. As well as skin, we have mucus snot is a really important barrier and a microbiome, the collective noun for the estimated 100tn microbes that live throughout our bodies, internally and externally. Some of these helpful bugs make antimicrobial chemicals and compete with pathogens for food and space.

Beneath these writhing swamps of mucus and microbes, our bodies are lined with epithelial cells which, says Cruickshank, are really hard to get through. They make antimicrobial products including, most relevant to coronavirus, antiviral compounds that are quite hostile.

If a pathogen breaches these defences, it has to deal with our white blood cells, or immune cells. One type, called macrophages, inhabit all our body tissue and, says Cruickshank, have all these weapons ready to go, but theyre not terribly precise. They report to the cleverer, adaptive white blood cells known as lymphocytes. They are the ones that remember germs, so if you meet that germ again, says Cruickshank, theyll just deal with it probably without you even knowing. Thats when youve got immunity and is the basis of vaccination. Its trying to bypass all the early stuff and create the memory, so you dont have to be sick.

Our immune systems may have blind spots. This might mean that our immune response doesnt recognise certain bugs, she says, or the bugs have sneaky evasion strategies. Personally, my immune system is not necessarily very good at seeing colds. But a healthy lifestyle will ensure your defences are as good as they get.

Seeing as our bodies contain more cells belonging to microbes, such as bacteria and yeasts, than human ones, lets start with the microbiome. We live in a symbiotic relationship with our gut bacteria, says Prof Arne Akbar, the president of the British Society for Immunology and a professor at University College, London. Having the right ones around, that we evolved with, is best for our health. Anything we do that alters that can be detrimental.

Not only do our microbes form protective barriers, they also programme our immune systems. Animals bred with no microbiome have less well developed immune responses. Older people, and those with diseases that are characterised by inflammation, such as allergies, asthma, rheumatoid arthritis and diabetes, tend to have less varied gut microbiomes.

To feed your gut flora, Cruickshank recommends eating a more varied diet with lots of high-fibre foods. Being vegetarian isnt a prerequisite for microbiome health, but the more plant foods you consume, the better. The microbiome really likes fibre, pulses and fermented foods, she adds.

Kefir yoghurt and pickles such as sauerkraut and kimchi are among the fermented delicacies now fashionable thanks to our increasing knowledge of the microbiome. But the evidence for taking probiotic supplements, she says, is mixed. Its not a dead cert that they will survive the journey through your digestive tract, or that they will hang around long enough if they do. Its more effective to change your diet, says Cruickshank.

The skin microbiome is important, too, but we know less about it. High doses of ultraviolet light (usually from the sun) can affect it negatively, weakening any protective functions (as well as triggering immune suppression in the skin itself). Overwashing with strong soaps and using antibacterial products is not friendly to our skin microbiomes. Combinations of perfumes and moisturisers might well also have an effect, says Cruickshank.

To be immunologically fit, you need to be physically fit. White blood cells can be quite sedentary, says Akbar. Exercise mobilises them by increasing your blood flow, so they can do their surveillance jobs and seek and destroy in other parts of the body. The NHS says adults should be physically active in some way every day, and do at least 150 minutes a week of moderate aerobic activity (hiking, gardening, cycling) or 75 minutes of vigorous activity (running, swimming fast, an aerobics class).

The advice for older people, who are more vulnerable to infection, is to do whatever exercise is possible. Anythings better than nothing, says Akbar. But a lifetimes exercise could significantly slow your immune system declining with age. In 2018, a study by University of Birmingham and Kings College London found that 125 non-smoking amateur cyclists aged 55 to 79 still had the immune systems of young people.

The other side of the coin, says Akbar, is elite athletes who become very susceptible to infections because you can exercise to a point where it has a negative impact on your immune system. This problem is unlikely to affect most of us unless, says Cruickshank, youre a couch potato and suddenly try and run a marathon, this could introduce stress hormones and be quite bad for your immune system.

One of the many happy side-effects of exercise is that it reduces stress, which is next on our list of immune-boosting priorities. Stress hormones such as cortisol can compromise immune function, a common example of which, says Akbar, is when chickenpox strikes twice. If you have had it, the virus never completely goes away. During periods of stress, he says, it can reactivate again and we get shingles.

Forget boozing through the coronavirus crisis, because heavy drinking also depletes our immune cells. Some studies have suggested that the first-line-of-defence macrophages are not as effective in people who have had a lot of alcohol, says Cruickshank. And theres been suggestions that high alcohol consumption can lead to a reduction of the lymphocytes as well. So if the bug gets into you, youre not going to be as good at containing and fighting it off.

Cruickshank says that vitamin D has become a hot topic in immunology. It is used by our macrophages, and is something that people in Britain can get quite low on in the winter. Necking extra vitamin C, however, is probably a waste of time for well-fed westerners. Its not that vitamin C isnt crucial to immune function (and other things, such as bone structure). All the vitamins are important, says Cruickshank, but vitamin C is water soluble, its not one that your body stores. Eating your five a day of fruits and vegetables is the best way to maintain necessary levels.

Exercising and eating well will have the likely knock-on effect of helping you sleep better, which is a bonus because a tired body is more susceptible to bugs. One study last year found that lack of sleep impaired the disease-fighting ability of a type of lymphocyte called T cells, and research is demonstrating the importance of our natural biorhythms overall.

Janet Lord, a professor at the University of Birmingham, recently showed that vaccinating people in the morning is more effective than doing so in the afternoon. Your natural biorhythms are, to some extent, dictated by sleep, says Akbar. If youve got a regular sleep pattern, you have natural body rhythms and everythings fine. If they go out of kilter, then youve got problems.

The seriousness of an infection largely depends on the dose you are hit with, which could in turn depend on how contagious the carrier is when they cough near you. Were constantly exposed to germs, and we only get sick from a handful of those, says Cruickshank.

If youre reasonably young and healthy, says Akbar, the mild benefits you may achieve from being extra good probably wont fend off a severe dose of coronavirus or flu. The likely scenario if you catch the infection is, he says, youll be sick for a while and you will recover.

From a public-health perspective, when nasty viruses such as coronavirus are doing the rounds, Akbars priority is not boosting already healthy peoples immune systems, but protecting the vulnerable people. Older people dont respond that well to the flu jab, though its better for them to have it than not. Its a general problem of immune decline with ageing.

When we get older, he says, the barrier function in the gut doesnt work that well, so you have something called leaky gut syndrome, where bugs creep into our bodies causing mild infections. This causes inflammation around the body, as does the natural accumulation of old zombie cells, called senescent cells, and inflammation compromises the immune response.

Akbar is working on developing drug treatments to reduce inflammation in older people but they are a way off yet. Age 65 is when, medically, one is considered older, but thats arbitrary, says Akbar. Some old people might get problems much earlier. And there are older people who are totally healthy.

In terms of coronavirus, says Cruickshank, its mostly spread by droplet transmission, as far as we can tell, so the biggest thing is hygiene. So wash your hands, and sneeze and cough into tissues, she suggests, between sniffles. No one can completely avoid getting sick, not even top immunologists.

Go here to read the rest:
How to boost your immune system to avoid colds and coronavirus - The Guardian

Read More...

Alternative methods to boost your immune system – WVNS-TV

Monday, March 9th, 2020

Posted: Mar 6, 2020 / 11:57 PM EST / Updated: Mar 6, 2020 / 11:57 PM EST

BECKLEY, WV (WVNS) With all the viruses going around, many of us are looking for ways to strengthen our immune systems.

On Point Health and Wellness in Beckley has safe alternative methods to keep your family healthy.

According to owner and licensed acupuncturist, Kacy Korczyk, acupuncture can naturally boost immunity and help with inflammation by releasing neuromodulators in the brain. She said you can also relax in the salt cave, and breathe in the therapeutic salt in the air. It is both anti-bacterial and antiviral.

Its really something super easy and super affordable, said Korczyk. You literally just go sit in a room and breath in salt air, and it can work wonders for your sinuses and respiratory tract along with skin issues It can also help with muscle tension and sleep as well.

People can use the salt cave anywhere from two to three times a week to once a month depending on your needs.

See original here:
Alternative methods to boost your immune system - WVNS-TV

Read More...

Are You At Higher Risk For Serious COVID-19 Illness? Here Is What To Do – Forbes

Monday, March 9th, 2020

With the COVID-19 coronavirus spreading, should older adults be flying? (Photo: Getty)

If you are 65 years of age or older or have a chronic medical condition, you may want to think twice about air travel given the COVID-19 coronavirus (SARS-CoV2) situation. Think twice may include trying to recall if you actually have your own private jet.

If you dont have your own airplane, then consider the recommendations that the Centers for Disease Control and Prevention (CDC) website now has for those at higher risk for bad COVID-19 outcomes. As the CDC website explains, older adults and people who have severe chronic medical conditions like heart, lung or kidney disease seem to be at higher risk for more serious COVID-19 illness. Early data suggest older people are twice as likely to have serious COVID-19 illness. (If you want to learn more about why such illnesses tend to be more serious in older adults, Miriam Knoll, MD has previously written for Forbes on this topic.) Nowhere on the CDC web page does it explicitly tell older individuals or those with weaker immune systems to avoid air travel. Nevertheless, take a look at the actual recommendations:

These recommendations dont exactly scream that its OK to get on a commercial flight. After all, commercial flights that arent ghost flights tend to have crowds on them called passengers. Completely avoiding other passengers might require either riding on the wing or spending the entire flight in the bathroom chanting, dont come in here. Theres bad stuff in here. Plus, how can you keep space between yourself and others when you are so close to your neighbors that you cant quite tell which seat belt is whose? These CDC web page even says, avoid crowds, especially in poorly ventilated spaces. And spring breeze is probably not the first thing that you think of when on a commercial flight.

Mike Stobbe reported for the Associated Press that the White House overruled health officials who wanted to recommend that elderly and physically fragile Americans be advised not to fly on commercial airlines because of the new coronavirus. However, Katie Miller, the Press Secretary for Vice President Mike Pence, tweeted the following about this AP report:

Regardless of who actually said what or did what, it is hard to reconcile the current CDC recommendations with older adults taking a commercial flight. Thus, if you are 65 years or older, have a chronic medical condition like diabetes, heart disease, lung disease, or cancer, are on medications such as steroids that may weaken your immune system, or have some other reason why your immune system may not at peak condition, you may want to do whatever you can to avoid air travel. That includes canceling or postponing flights if feasible. Unless, of course, you have your own plane.

In fact, other aspects of the CDC recommendations essentially paint the general picture that older individuals and others with weaker immune systems should begin to distance themselves from others. That doesnt mean start acting aloof and cold and saying, bye, Felicia to everyone. Rather, it means maintaining more physical distance from others. If you are in the higher risk group, prepare to spend more time at home.

When you are older or have chronic medical medical conditions, the recommendation usually isnt too interact less with people. In fact, meeting new people can be a great way to cope with loneliness and other challenges. But these are not typical times. A potentially deadly and not yet well-understood infectious disease is spreading and the situation continues to evolve. Social distancing doesnt mean cut off all social ties. Technology now allows you to maintain and even grow social ties without always having to be physically next to each other. For example, you can start a massive amount of different hashtags or like everything that everyone says on Twitter. The CDC also isnt recommending that you become a hermit. Just make sure that face-to-face interaction is not literally face-to-face. Also, make sure that the people you do interact with in person are not sick and know what precautions to take to keep themselves and you from getting infected.

Go here to read the rest:
Are You At Higher Risk For Serious COVID-19 Illness? Here Is What To Do - Forbes

Read More...

Behind the scenes, scientists prep for COVID-19 vaccine test – Northwest Herald

Monday, March 9th, 2020

WASHINGTON A team of scientists jostled for a view of the lab dish, staring impatiently for the first clue that an experimental vaccine against the new coronavirus just might work.

After weeks of round-the-clock research at the National Institutes of Health, it was time for a key test. If the vaccine revs up the immune system, the samples in that dish blood drawn from immunized mice would change color.

Minutes ticked by, and finally they started glowing blue.

Especially at moments like this, everyone crowds around, said Kizzmekia Corbett, an NIH research fellow leading the vaccine development. When her team sent word of the positive results, it was absolutely amazing.

Dozens of research groups around the world are racing to create a vaccine as COVID-19 cases continue to grow. Importantly, theyre pursuing different types of vaccines shots developed from new technologies that not only are faster to make than traditional inoculations but might prove more potent. Some researchers even aim for temporary vaccines, such as shots that might guard peoples health a month or two at a time while longer-lasting protection is developed.

Until we test them in humans, we have absolutely no idea what the immune response will be, cautioned vaccine expert Dr. Judith ODonnell, infectious disease chief at Penn Presbyterian Medical Center. Having a lot of different vaccines with a lot of different theories behind the science of generating immunity all on a parallel track really ultimately gives us the best chance of getting something successful.

First-step testing in small numbers of young, healthy volunteers is set to start soon. Theres no chance participants could get infected from the shots, because they dont contain the virus itself. The goal is purely to check that the vaccines show no worrisome side effects, setting the stage for larger tests of whether they protect.

First in line is the Kaiser Permanente Washington Health Research Institute in Seattle. It is preparing to test 45 volunteers with different doses of shots co-developed by NIH and Moderna Inc.

Next, Inovio Pharmaceuticals aims to begin safety tests of its vaccine candidate next month in a few dozen volunteers at the University of Pennsylvania and a testing center in Kansas City, Missouri, followed by a similar study in China and South Korea.

Even if initial safety tests go well, youre talking about a year to a year and a half before any vaccine could be ready for widespread use, stressed Dr. Anthony Fauci, director of NIHs National Institute of Allergy and Infectious Diseases.

That still would be a record-setting pace. But manufacturers know the wait required because it takes additional studies of thousands of people to tell if a vaccine truly protects and does no harm is hard for a frightened public.

I can really genuinely understand everybodys frustration and maybe even confusion, said Kate Broderick, Inovios research and development chief. You can do everything as fast as possible, but you cant circumvent some of these vital processes.

Behind-the-scenes in NIHs lab

The new coronavirus is studded with a protein aptly named spike that lets the virus burrow into human cells. Block that protein, and people wont get infected. That makes spike the target of most vaccine research.

Not so long ago, scientists would have had to grow the virus itself to create a vaccine. The NIH is using a new method that skips that step. Researchers instead copy the section of the virus genetic code that contains the instructions for cells to create the spike protein, and let the body become a mini-factory.

Inject a vaccine containing that code, called messenger RNA or mRNA, and peoples cells produce some harmless spike protein. Their immune system spots the foreign protein and makes antibodies to attack it. The body would then be primed to react quickly if the real virus ever comes along.

Corbetts team had a head start. Because theyd spent years trying to develop a vaccine against MERS, a cousin of the new virus, they knew how to make spike proteins stable enough for immunization, and sent that key ingredient to Moderna to brew up doses.

How to tell its a good candidate to test in people?

Corbetts team grew spike protein in the lab lots of it and stored it frozen in vials. Then with the first research doses of vaccine Moderna dubbed mRNA-1273, the NIH researchers immunized dozens of mice. Days later, they started collecting blood samples to check if the mice were producing antibodies against that all-important spike protein. One early test: Mix the mouse samples with thawed spike protein and various color-eliciting trackers, and if antibodies are present, they bind to the protein and glow.

Corbett said the work couldnt have moved so quickly had it not been for years of behind-the-scenes lab testing of a possible MERS vaccine that works the same way.

I think about it a lot, how many of the little experimental questions we did not have to belabor this time around, she said. When she saw the first promising mouse tests, I felt like there was a beginning of all of this coming full circle.

___

INOVIOS APPROACH

Inovios approach is similar -- again using genetic code, in this case packaged inside a piece of synthetic DNA that acts as the vaccine. One advantage Broderick cites for a DNA approach is that unlike many types of vaccines, it may not need refrigeration.

A MERS vaccine that Inovio designed the same way passed initial safety studies in people, paving the way for testing the new COVID-19 vaccine candidate. Inovio is doing similar animal testing to look for presumably protective antibodies.

While it gets ready for human safety tests, Inovio also is prepping for another piece of evidence whats called a challenge study. Vaccinated animals will be put in a special high-containment lab and exposed to the new coronavirus to see if they get infected or not.

___

PLACEHOLDER VACCINES?

Regeneron Pharmaceuticals is exploring a different approach: simply injecting people with coronavirus-fighting antibodies instead of teaching the body to make its own. This method could provide temporary protection against infection or work as a treatment for someone already infected.

Regeneron vaccinated mice genetically engineered to make human antibodies. From small blood samples, researchers culled hundreds of different antibodies, and now theyre teasing out which seem most potent against that notorious spike protein, said Christos Kyratsous, Regenerons chief of infectious disease research.

Regeneron developed this monoclonal antibody approach as a life-saving treatment for Ebola. Last year, it performed a successful safety test of experimental antibodies designed to fight MERS.

The difference between using antibodies as a treatment or a vaccine? Low-dose shots in the arm every few months might give enough antibodies to temporarily ward off infection, while treatment likely would require far higher doses delivered intravenously, Kyratsous said. Regeneron is pursuing both, and hopes to begin first-step safety testing in early summer.

The antibodies are the same, he said. We would like to have an antibody that is as flexible in administration as possible.

Whichever of these approaches, or others in the pipeline, pan out, NIHs Corbett said scientists one day hope to have vaccines on the shelf that could be used against entire families of viruses. One frustration when scientists have to start from scratch is that outbreaks too often are waning by the time vaccine candidates are ready for widespread testing.

This is the fastest we have gone, Fauci said of the NIHs vaccine candidate, although he warned it might not be fast enough.

Still, he called it quite conceivable that COVID-19 will go beyond just a season, and come back and recycle next year. In that case, we hope to have a vaccine.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Department of Science Education. The AP is solely responsible for all content.

Originally posted here:
Behind the scenes, scientists prep for COVID-19 vaccine test - Northwest Herald

Read More...

Men far more likely to die from coronavirus than women, analysis shows – Telegraph.co.uk

Monday, March 9th, 2020

Coronavirus is far more deadly for men than women, with males 65 per cent more likely to die from an infection than females, new analysis shows.

The latest breakdown of figures from the World Health Organisation (WHO) and Chinese scientists shows that, of all suspected cases, 1.7 per cent of women who contract the virus will die compared with 2.8 per cent of men.

In confirmed cases, the infection is fatal for 4.7 per cent of men but just 2.8 per cent of women, even though the gender balance for those testing positive is roughly split in half.

Some experts believe the sex imbalance relates to a higher prevalance of smoking or chronic alcohol use among men, while others think men are more likely to have underlying health conditions such as heart disease and diabetes, making them more vulerable to an infection.

During the height of the Wuhan epidemic, 16 per cent of people receiving dialysis at Remnin Hospital contracted the disease, and 16 per cent died.

Although the overall global death rate is still being calculated, with estimates ranging from one to 3.8 per cent, the analysis by Worldometer shows it jumps hugely when people have health problems.

The risk of death rises to 10.5 per cent for people with cardiovascular disease, 7.3 per cent for diabetics, 6.3 per cent for those with chronic respiratory disease, six per cent for people with high blood pressure and 5.6 per cent for cancer sufferers.

However, Paul Hunter, professor of medicine at the University of East Anglia, believes women may simply have better immune systems and are biologically better at fighting off the virus.

"Some of the differences are probably due to men smoking more and being chronic abusers of alcohol, but also, women are intrinsically different to men in their immune response," he said.

"Sometimes that works in women's favour. Women seem to have more powerful immune systems, which means they suffer more from autoimmune disease like rheumatoid arthritis, when the immune system responds over-aggressively and ends up attacking the body.

"This happens in men far less frequently, but itappears to be a good thing for a number of infections and particularly influenza, and there is evidence women produce better antibody responses to the influenza vaccine than men."

Older men may be particularly at risk because the death rate rockets in the elderly.

While the chance of dying from the virus for anyone under 50 is less than 0.5 per cent, it jumps to 1.3 per cent after the age of 50 and then nearly trebles to 3.6 per cent after 60.

By the time someone reaches 70, their risk of dying has hit eight per cent, which then rises to 14.8 per cent for the over 80s, far and away the most vulnerable group.

On Thursday evening,NHS Berkshire confirmed that the first person to die in Britain was an "older patient with underlying health conditions".

The British man who died after contracting the virus on the Diamond Princess cruise ship, which was quarantined off the Japanese coast, was in his 70s.

Although many older people are often suffering from chronic disease which make them more vulnerable, the immune system itself begins to break down in later life.

Diseases that are largely harmless in youth, such as chicken pox, hide in the body and can become deadly shingles as people get older and their immunity begins to decline. The quality of antibodies produced also diminishes with age, preventing the body from clearing out viruses quickly and efficiently.

"Our immune systems start giving up the ghost," added Prof Hunter. "You're going to delay coming up with an antibody."

Yet young children seem to be oddly protected against coronavirus. So far there have been no deaths among the under 10s, and the disease is fatal for just 0.2 per cent of people aged between 10 and 40.

Dr Andrew Freeman, a reader in infectious diseases at Cardiff University, said: "I think, with children, it is likely that they are susceptible to infection but more likely get mild/asymptomatic infection.

"This does occur with some other viral infections such as Epstein-Barr virus infection which causes glandular fever in young adults, and also hepatitis A. We still have a lot to learn about this virus."

Read the original here:
Men far more likely to die from coronavirus than women, analysis shows - Telegraph.co.uk

Read More...

Health officials say not to touch your face. That’s harder than it sounds even for them. – USA TODAY

Monday, March 9th, 2020

USA TODAY answers a question you may be wondering: Is coronavirus worse than the flu? USA TODAY

You might be buying or making lots ofhand sanitizerto help protect yourself from the COVID-19 coronavirus, but health care professionals areasking you to do something a lot harder: Stop touching your face.

In addition to properly washing your hands, experts saykeeping your hands away from your eyes, nose and mouth will help protect you from the coronavirus orthe flu and other infections.

Easier said than done.

"Even health experts have trouble not touching their faces!" the Santa Clara County, California Public Health Department posted to Facebook on Thursday.

That followed an article bythe Washington Post pointing out thatSara Cody, the county's public health director, had licked her finger moments after urging the public not to touch their face.

Its just subconscious behavior," infection prevention expertConnie Steed told USA TODAY on Friday.

She said trying to break the habit has taken a big effort for her and her family.

But it's a habit worthbreaking.

Your face contains multiple pathways for infections to easily enter your body, and your hands can be contaminated without you knowing it.

You can clean your hands all day, but as soon as you start touching things again ...the germs on your hands increase, said Steed,the president of theAssociation for Professionals in Infection Control and Epidemiology.

Hand washing: You're probably washing your hands wrong and don't even know it

Watch: Boost your immune system by doing these things and fend off coronavirus, flu

If we could only see the germs on our hands, we'd find it a lot easier to keep them away from our face,Steed said.

Reducing how often you touch your face is just part of "common-sense basics" for avoiding all types of illnesses, not just the coronavirus currently causing widespread anxiety.

Because it's a common habit most people do it all the time without realizing it. APIC estimates the average person touches their face23 times per hour, based on a small 2015 study.

It's something we start doing as young kids and most of us never stop, Steed said. Becoming self-aware of the problem is a good place to start.

That's what Verge journalistElizabeth Lopatto tried to do this week asshe attempted to count how often she touched her face in a day.

After a few hours she concluded "I am aborting the mission because I touch my face too often."

How-to guidesare popping upeverywhere.

One common thread: Try your best to do it less, but don't let it ruin your day. As one expert pointed out to the New York Times, stress is bad for your immune system and obsessing over breaking a common habit could create its own problems.

According Steed, there are a few simple things that may help:

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/news/health/2020/03/08/coronavirus-prevention-how-stop-touching-your-face/4965517002/

Read more from the original source:
Health officials say not to touch your face. That's harder than it sounds even for them. - USA TODAY

Read More...

How Long Will It Take to Develop a Coronavirus Vaccine? – The New Yorker

Monday, March 9th, 2020

On Monday, Donald Trump held a meeting in the White House to discuss his Administrations response to COVID-19, the novel coronavirus that has spread to every continent except Antarctica. At the time there had been more than a hundred and five thousand cases reported in at least eighty-three countries, leading to more than thirty-five hundred deaths. Seated around an oval table in the Cabinet Room were health experts from the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health, as well as pharmaceutical executives from Pfizer, Johnson & Johnson, Sanofi, and others. With more than a hundred cases already discovered in the U.S., which had resulted in six deaths (the virus has since infected nearly four hundred people in the U.S., and killed at least nineteen of them), Trump was concerned. But he was also confused, despite having had several previous briefings with the Administrations top health officials. Grasping for some good news, he pressed the executives to deliver a vaccine within a few months, at which point Anthony Fauci, the longtime director of the National Institute of Allergy and Infectious Diseases (N.I.A.I.D.), spoke up. A vaccine that you make and start testing in a year is not a vaccine thats deployable, he said. The earliest it would be deployable, Fauci added, is in a year to a year and a half, no matter how fast you go.

The virus seems to have been circulating in the United States, particularly in Washington State, for the past month, and more cases are expected. A person can be infected but asymptomatic, and therefore unknowingly infect other people. This limits the ability of public-health tools to contain its spread. Even still, a COVID-19 vaccine developed, licensed, and manufactured at a global scale in twelve months would be an unprecedented, remarkable, even revolutionary achievement. No other vaccine has come close to being developed that quickly. The fastest effort to date was during the Zika outbreak, in 2015, when one was ready for testing in about seven months, but the epidemic fizzled out before an approved vaccine could be sent through clinical trials. At the meeting on Monday, Trump said, I like the sound of a couple months better, if I must be honest.

John Shiver, the global head of vaccine research and development at the multinational pharmaceutical company Sanofi, which is developing a COVID-19 vaccine, was at the meeting with Trump. There was some confusion there, Shiver said, that certain officials did not understand that being in people, as in human trials, is not the same as having a product. Clinical trials are conducted on healthy people, which is inherently challenging. You certainly dont want a vaccine that can make it worse, Shiver said. There have been some vaccine candidates historically that could actually enhance the disease. Sanofi is working with the United States Biomedical Advanced Research and Development Authority, a sort of biomedical DARPA, to advance a COVID-19 vaccine based largely on the vaccine candidate it had developed for SARS. Shiver told me that the authority doesnt expect to have anything ready for human trials until much later this year. Its difficult, Shiver said, to see how, even in the case of an emergency, a vaccine could be fully ready for licensure in a year and a half.

The Coalition for Epidemic Preparedness Innovations (CEPI), an Oslo-based nonprofit organization, was established at Davos, in 2017, to help the world prepare for a disease X pandemic. One of its aims is to dramatically hasten the process of vaccine development. To create a viable, scalable vaccine takes vast amounts of funding and R. & D., Rachel Grant, the advocacy and communications director at CEPI, told me. It is a long and complex business. Its all doable, science can meet the challenges, but there is lots of attrition before any vaccine gets to the point of licensure. The problem is twofold. First, there may never be a market for a vaccine at the end of the development process, because the epidemic is contained, or never comes to pass. Then, traditionally, if there is an epidemic, it may take hold in a developing country where the costs of research and development cannot be recouped. The resources and expertise sit in biotech and pharma, and theyve got their business model, Grant said. Theyre not charities. They cant do this stuff for free.

CEPI, with funding from the government of Norway, the Gates Foundation, the Wellcome Trust, and several other countries (the United States is not among them), is trying to bridge the gap. The challenge of vaccine development is what CEPI was set up to solve, Grant told me, played out writ large in an episode like this. Since the novel coronavirus emerged, CEPI has ramped up its grant-making expenditures to more than nineteen million dollars. Two grant recipientsa Massachusetts-based biotech startup named Moderna and a lab at the University of Queensland, in Brisbane, Australiahave, remarkably, already developed a vaccine candidate that they will start testing in human trials in the next few months, and another biotech startup supported by CEPI is not far behind. But, ultimately, to get three different vaccines through the final phase of clinical testing, Nick Jackson, CEPIs head of programs and innovative technology, told me, will require an estimated two billion dollars.

Barney Graham is the deputy director of the Vaccine Research Center, at the N.I.A.I.D., in Bethesda, Maryland, which is collaborating with Moderna and other academic labs on a possible vaccine. Graham is one of the worlds experts on the structure of viruses and how they interact with human cells to make us sick. In the seven years before the COVID-19 virus appeared, one of Grahams projects had involved understanding the MERS coronavirus, in order to potentially develop a vaccine. (MERS, which can be transmitted from camels to humans, has been contained to the Middle East, and seems to spread mostly in confined spaces, like hospitals.) Theres several ways of delivering a protein to a human body that will make a vaccine-type response, he told me. Certain proteins, when injected into a human, are antigenic, provoking the bodys immune system to create antibodies. Traditionally, proteins are made in a microbrewery type of bioreactor, Graham saida common flu-virus vaccine, for instance, is grown in chicken eggsand it takes up to two years to get that protein ready. That is not fast enough if youre in a pandemic situation. Researchers have long been working on so-called vaccine-platform manufacturing technologies for future use. The idea is akin to creating a frozen-yogurt maker for vaccinessame machine, different flavors. With vaccine-platform technologies, the hope is that the way in which the vaccine is manufactured and delivered to the bodysuch as Modernas messenger-RNA (mRNA) technologywill transport any antigen and, therefore, theoretically protect against any infectious disease. You can make the RNA in the same way, purify it in the same way, release it in the same way, and yet make many different proteins, Graham said.

Read the original here:
How Long Will It Take to Develop a Coronavirus Vaccine? - The New Yorker

Read More...

CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140) – GlobeNewswire

Monday, March 9th, 2020

Coronavirus Can Quickly Progress to Severe Pneumonia and Even Death Due to Immune Hyperactivity Including Acute Respiratory Distress Syndrome (ARDS); CytoDyn's Trial Focuses on Patients Who Develop Mild-To-Moderate Respiratory Illness After Contracting Coronavirus

CytoDyn Negotiating to Expedite Setup of Treatment Clinics in New York and San Francisco

VANCOUVER, Washington, March 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to conduct a Phase 2 clinical trial with leronlimab (PRO 140) as a therapy for patients who experience respiratory complications as a result of contracting the coronavirus disease 2019 (COVID-19).

Bruce Patterson M.D., CEO of IncellDX and advisor to CytoDyn explains: Leronlimab inhibits migration of Tregs, which can inhibit the innate immune response against pathogens, into areas of inflammation. Most importantly, the migration of macrophages and the release of inflammatory cytokines including TNF and IL-6 (cytokine storm) is what causes the profound damage in the lungs in some patients. Leronlimab binding to CCR5 changes the macrophages migration and cytokine production. Taken together, these activities may reduce the morbidity and mortality in moderate to severe cases of COVID-19. IncellDx has developed a suite of diagnostics to monitor these effects of leronlimab on the immune system in these critical patients.

Coronavirus deaths are linked to patients immune systems that have an inflammatory response to the virus causing Acute Respiratory Distress Syndrome (ARDS). With ARDS, the entire lung is affected, unlike pneumonia where often only part of the lung is affected, said Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn. Our scientists believe that our data in cancer patients indicated that leronlimabs role in blocking Tregs and macrophages demonstrates that leronlimab modulates the inflammatory response to more effectively provide effector function. With more than 840 patients treated with leronlimab in our clinical trials, we believe leronlimab could reduce the inflammation which contributes to ARDS, thereby potentially reducing morbidity and mortality rates in coronavirus patients. If we can show a similar response in our current Phase 2 trial, then leronlimab could have a powerful impact on improving the prognosis for coronavirus patients. With leronlimabs Fast Track designation from the FDA for the treatment of HIV and mTNBC (triple-negative breast cancer), we are expediting the initiation of this trial to address the rapid spread of this disease and are eager to test this proof of concept in clinical trials as a potential treatment for coronavirus, added Dr. Pourhassan.

The following is a brief summary of excerpts from the Companys Phase 2 clinical trial protocol:Indication for Use: Leronlimab is indicated for treatment of adult patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.Objective: The purpose of this study is to assess the safety and efficacy of leronlimab administered as weekly subcutaneous injection in subjects with coronavirus 2019 infection.Primary Outcome (Endpoint) Measure: Clinical Improvement based on change in total symptom score (for fever, myalgia, dyspnea and cough)Note: The total score per patient ranges from 0 to 12 points. Each symptom is graded from 0 to 3 [0=none, 1=mild, 2=moderate, and 3=severe].Trial Design: This is a Phase 2, single arm, open-label, multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection. Leronlimab (PRO 140) will be administered subcutaneously as weekly dose of 700 mg.The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.Treatment Period: 4 weeks allowed windows.Inclusion Criteria:

About Coronavirus Disease 2019The coronavirus disease 2019 (COVID-19) was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.1 The origin of COVID-19 is uncertain and it is unclear how easily the virus spreads. COVID-19 is thought to be transmitted person to person through respiratory droplets, commonly resulting from coughing sneezing and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough and shortness of breath. It is believed that symptoms of COVID-19 may appear in as few as two days or as long as 14 days prior to exposure, and that symptoms in patients have ranged from non-existent to severe and fatal. There are currently no known antiviral treatments effective at suppressing COVID-19.

About Leronlimab (PRO 140)The U.S. Food and Drug Administration (FDA) have granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is therefore conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additionalclinical studies when appropriate.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Companys cash position, (ii)the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv)the Companys ability to enter into partnership or licensing arrangements with third parties, (v)the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Companys ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Companys clinical trials, (viii)the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com

References:1.Novel Coronavirus 2019, Wuhan, China. (2020, January 24). Retrieved fromhttps://www.cdc.gov/coronavirus/2019-ncov/index.html

See more here:
CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140) - GlobeNewswire

Read More...

The Pattern That Epidemics Always Follow – The Atlantic

Monday, March 9th, 2020

A pestilence isnt a thing made to mans measure, Albert Camus observed in The Plague. Therefore we tell ourselves that pestilence is a mere bogey of the mind, a bad dream that will pass away. Panic is exhausting. Only so many witches can be tossed into wells or rolls of toilet paper hoarded before knee-jerk anxiety progresses to a steady state of fear. Cities go dark, governments quarantine exposed populations, institutions begin shutting down, and, as we have seen with the erratic stock market, economies sputter. A population huddled indoors cant till the fields or man the pin factories. Oxen, asses, sheep, goats, pigs, and chickens and even dogs . . . were driven away and allowed to roam freely through the fields, Giovanni Boccaccio wrote in the Decameron. The crops lay abandoned.

According to Cirium, an aviation-industry consulting firm, more than 200,000 flights in and out of China have been canceled, a 60 percent decline. In 2003, in the midst of SARS, global air travel was down 25 percent. Planes flew into Chek Lap Kok, Hong Kongs international airport, completely empty of passengers. Hong Kong, a city renowned for its shopping, became a retail ghost town. The eighth-of-a-mile walk from one Prada boutique in Hong Kongs Admiralty district to another Prada boutique in Central, usually a 30-minute journey due to all the jukes and spin moves required to avoid the throngs of mainland shoppers, was now a five-minute straight shot.

Concerned about the health of my staff at Time Asia, I consulted other managers at various subsidiaries of what was then the Time Warner empire. The local boss of CNN was in New York with his family and would be staying there for the duration of the outbreak. The head of Turner Entertainment Asia hadnt made any plans, but was eager to hear what I had in mind. Nothing was more fatal, Defoe had warned, then the supine negligence of the people themselves. Determined not to repeat the folly of Defoes Londoners, I did what managers everywhere do when they want to look like they know what they are doing: I convened a meeting. But when I suggested that anyone who had been in contact with a possible SARS case should stay away from the office, it became clear that everyone in the room already knew someone who might be infected. In fact, our circulation manager had dined the evening before at her father-in-laws apartment at Amoy Gardens. There was really nothing we could do, I realized, besides shutting down our publication. But that wasnt an option: We were a newsmagazine, and this was news.

Fear dissipates eventually, replaced by a more realistic sense of the risks. An epidemic, even one of a disease as seemingly easy to transmit as COVID-19, while burdening public-health systems and potentially deadly for the elderly and those with compromised immune systems, is eminently survivable by the majority of the population. This fact becomes obvious as people become sick, yet recover; doctors and nurses get a better handle on treatment; and most people go about their life and never succumb. In some ways we were lucky at Time Asia, because we had no choice but to continue visiting hospitals, talking with doctors, and interviewing virologists. We were worried, yes, but proximity to the professionals gave us clarity about the actual risks we were facing.

Follow this link:
The Pattern That Epidemics Always Follow - The Atlantic

Read More...

Stronger Immune Systems Fight The Risk Of Infection – Longevity LIVE

Monday, March 9th, 2020

Stronger immune systems are what we all need in order to successfully shield ourselves from being infected by harmful viruses and bacteria. Especially with the outbreak of the Coronavirus, this gives us even more reason to ensure that we build stronger immune systems. With or without the recent outbreak, we should be taking preventative measures in any case.

If we build stronger immune systems, our bodies will be more equipped to fend off viruses and bacterial attacks. To do this we must all practise good eating habits and choose food that builds stronger immune systems. This way you wont have to stress or panic as much as those who have weaker immune systems. Mainly because your body is ready for battle against any illnesses.

The point is not to panic but to instead focus on your own health. Not only does a strong immune system help fight infections caused by viruses, but it will also speed up the recovery process after an infection. Dont underestimate the power of your immune system. When youve got a strong one, it acts as your bodys defence against infectious organisms and other invaders.

For things first, what is the immune system? Basically it is a complex system in your body that is made up of a network of cells, tissues and organs that work together to protect the body. According to doctors, everyones immune system is different due to factors such as age, eating habits and lifestyle.

Therefore, it is important to make sure that your immune system is strong and fit to fight. Especially in times like these where unknown illnesses are on the loose. You need to look after your health and prioritize your protection. In fact, even if you think youre very healthy you should consider doing a few things to boost your immune system for additional protection against viruses. While there are no guarantees that taking these steps will help, they are very unlikely to hurt.

The most important tip from all health professionals:Wash. Your. Hands. Seems logical right? Well, just ensure youre doing it properly. And if you dont have any access to clean running water then you can also use hand sanitizer with at least 60 percent alcohol. There are also organic hand sanitizers available if youre worried about the environment.

Were going to share some useful tips to build stronger immune systems. Just be sure to remember to check in with your personal doctor or health professional before any change in your habits. Even if its just taking vitamin supplements or starting an exercise program.

Experts in health explain that one of the most important vitamins to build stronger immune systems is vitamin C. Why? Because when theres a lack of vitamin C it can make you more prone to getting sick.

Moreover, your body needs Vitamin B6, because it is vital in supporting biochemical reactions in the immune system. In addition to this, vitamin E is also a powerful antioxidant that aids the body in fighting off infections. This means that its very important to get enough vitamins for stronger immune systems. You should be able to do this with a healthy and balanced diet.

We think that in light of the current outbreak, it will work in your favor to consume food that boosts the immune system. You can start by making sure your diet includes green vegetables, kiwi fruits, lemons and oranges. In addition, you can also consume nuts like almonds and cashews, which are high in vitamins and antioxidants.

Youll be glad to hear that cooked poultry and shellfish are also important immune boosters due to the protein and zinc they provide. However, experts warn us to avoid consuming half-cooked or raw food for a while. Shellfish that are high in zinc include crab, clams, lobster and mussels. Take note of the daily recommended amount (11mg for men and 8mg for women). Too much zinc can inhibit the immune system.

Then it is also integral that you dont develop any vitamin D deficiencies. This may lead you to encounter poor bone growth, cardiovascular problems and a weak immune system. Therefore, you need to choose supplements that contain D3 (cholecalciferol) since its good for raising your blood levels of vitamin D. Nutritionists recommend a balanced diet comprising carbohydrates, proteins, fats, vitamins and minerals. And of course, drinking enough water is essential to building stronger immune systems.

Any health expert will inform you that a diet rich in colorful fruits and vegetables is important for the body. These foods help to replenish and build stronger immune systems. Moreover, fruits and vegetables contain Vitamin C, E and antioxidants that all enhance the immune system to fight against infections and pathogens.

Its best to eat a variety of citrus fruits and berries for a strong immune system. Then in terms of vegetables, consume bell peppers, broccoli and spinach. Just like anything though, be sure to consume these in moderation. Usually, people without any underlying health issues will not be affected by slightly higher intake. However, if you have a pre-existing health condition be cautious about dietary changes, especially if youve had any medical procedures done, for example to the heart, its best to consult a nutritionist for a customised regime.

You may also want to include more seeds into your diet. These are essential for boosting the immune system. For example, sunflower seeds contain phosphorous, magnesium and Vitamin B6. To get more vitamin E you can try including more avocados, dark leafy greens and nuts. Lots of research also points to eating more garlic, ginger, dark chocolate and green tea. These are highly beneficial to the body. Be sure to also include Vitamin D and probiotics from yogurt to build stronger immune systems. Essentially its best to stay away from any processed food.

Its also important to avoid high-sugar food and drinks as they may weaken your immunity, accumulate unnecessary fats or lead to other medical problems. To really maximise your healthy immune system, complement your healthy diet with regular and moderate amounts of exercise.

Never skimp on your sleep. Getting quality sleep will help build stronger immune systems. Why? Sleep helps your T cells stick to and attack infections. So when you miss out on sleep your T cells are less sticky and arent as strong in fighting off viruses.

Every person is different when it comes to sleep requirements. However, the general guidelines state that we need between 7 and 9 hours of solid sleep each night. If you have restless sleep, wake up every night or snore, you may want to talk to a doctor.

Whatever you do, just dont panic. This is because anxiety weakens the immune system. In fact, being stressed can cause your body to release extra cortisol, which over time can negatively affect sleep quality and your immune system. A well-rested body will build stronger immune systems. Apparently acupuncture is also very beneficial to building stronger immune systems.

The aim of the game is to do all that we can to build stronger immune systems, so we dont have to panic or stress too much about the risk of getting infected. Take care of yourselves.

To be healthy means to maintain an optimal balance of all the functions in your body. Eating good food is the best way to get the right balance of vitamins and minerals. Heres how.

Make Sure Immune System Is Strong And Fit To Fight. New Straits Times. https://www.nst.com.my/news/nation/2020/01/560946/make-sure-immune-system-strong-and-fit-fight

How to Boost Your Immune System to Help Avoid Coronavirus COVID-19. Alexandria Living. https://alexandrialivingmagazine.com/health-wellness/how-to-boost-immune-system-coronavirus-2020/

Play Good Defense With These 66 Ways to Boost Your Immune System During Flu Season. Parade. https://parade.com/992175/marysauer/how-to-boost-immune-system/

Read this article:
Stronger Immune Systems Fight The Risk Of Infection - Longevity LIVE

Read More...

Kate Hawkesby on coronavirus: We need to be proactive, not panicky – Newstalk ZB

Monday, March 9th, 2020

I dont know about you but Im getting Coronavirus fatigue.

Like all news cycles, I feel like its run its course of being front page headline fodder. The glaring example of that was yesterdays No new cases headline. We are now reporting that there is nothing to report.

One of the key things Ive learned throughout all this is that not living in fear and instead working to support our immune systems is a very good idea. It sure beats the alternative, which is to panic.

Being proactive about being preventative applies to all healthcare, but we so often focus on the fixes at the bottom of the cliff, instead of dealing to it at the top. Yes, we should wash hands and clean communal surfaces, but also, we should be boosting our immune systems so the chances of us getting anything at all are reduced.

So how do we do that?

Well, according to what Ive read, by reducing stress (that includes reducing how much youre stressing about Coronavirus), by getting good sleep, by eating well, by regularly exercising - all the things we know we should do, but often forget to.

By reducing our consumption of social media, by acknowledging that not everything we read needs to be alarmist and taken at face value.

But also, did you know you can even boost your immune system by just being positive? Easier said than done a lot of the time, but still, its worth a shot.

I also think it benefits our kids too, who have enough to worry and be anxious about with global warming, the ice caps melting and everything else theyre taught to be afraid of. I dont know that parents panic buying toilet paper and donning face masks is the most reassuring thing for kids to see. Especially when its not necessary.

I was at the supermarket with my daughter yesterday and we saw about three people with face masks on while we were there. She asked me if they had Coronavirus, I told her probably not, but perhaps they just dont want it and theyre being extra careful.

She asked if we should have masks on. I said no. But you can see how panic leads to panic. I was panicking about the shopping itself, that if I saw toilet paper maybe I should snap it up because the panic buyers were making me panic that its running out!

My mother in law was up from Christchurch this weekend and she was bemused by it all, what she called a very Auckland thing. But its not just Auckland, there have been arrests and tasers and all out punch ups in Australia over panic buying, Tescos in the UK has had to start rationing, Italy went beserk emptying shelves, so were not alone.

But with our number of confirmed cases sitting globally speaking very low at five, I think its prudent we all take some positive action like trying to boost our immune systems, rather than fear-driven actions like panic buying hand sanitizer.

Go here to read the rest:
Kate Hawkesby on coronavirus: We need to be proactive, not panicky - Newstalk ZB

Read More...

Molecular Genetics – an overview | ScienceDirect Topics

Monday, March 9th, 2020

Wayne W. Grody, Joshua L. Deignan, in Emery and Rimoin's Principles and Practice of Medical Genetics, 2013

This article is a revision of the previous edition article by Wayne W Grody, volume 1, pp 601626, 2007, Elsevier Ltd.

Molecular genetic testing has a unique range of indications, most of which are quite different from the uses of traditional clinical laboratory testing and even molecular biologic testing in other disease classes (e.g. infectious disease, cancer). The technical approaches as well as the psychosocial and ethical implications of molecular genetic tests may vary substantially depending on the reason for testing (e.g. diagnostic, carrier screening). Just as many of the applications are unique, so too the types of patient samples collected for molecular genetic testing may be different from those obtained for other types of clinical laboratory testing. In addition, the choice of technique will depend on the nature of the disease gene being studied (especially its size and mutational heterogeneity), the purpose of the test, and to some extent the condition of the specimen, and examples of specific conditions are discussed. Finally, high complexity laboratories performing molecular genetic testing need to be aware of the specific regulatory considerations involved.

Originally posted here:
Molecular Genetics - an overview | ScienceDirect Topics

Read More...

Ross Prize Awarded to Cold Spring Harbor Laboratory Professor – Yahoo Finance

Monday, March 9th, 2020

Dr. Adrian R. Krainer, pioneer in neuromuscular disease treatment to be honored at June 8 symposium in New York City

The Feinstein Institutes for Medical Research has selected Adrian R. Krainer, PhD, St. Giles Foundation Professor at Cold Spring Harbor Laboratory, as the eighth awardee of the Ross Prize in Molecular Medicine. The prize is awarded annually through the Feinstein Institutes peer-reviewed, open-access journal, Molecular Medicine, and includes a $50,000 award that will be presented to Dr. Krainer on June 8 at the New York Academy of Sciences (NYAS) in Manhattan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005570/en/

Dr. Adrian R. Krainer (Credit: Cold Spring Harbor Laboratory)

The Ross Prize is made possible by the generosity of Feinstein Institutes board members Robin and Jack Ross. It is awarded to scientists who have made a demonstrable impact in the understanding of human disease pathogenesis and/or treatment and who hold significant promise for making even greater contributions to the general field of molecular medicine. Dr. Krainer is being recognized for his pioneering work in introducing antisense therapy in clinical use, and for its successful application to spinal muscular atrophy.

Dr. Krainer studies the mechanisms of RNA splicing, ways in which they go awry in disease, and the means by which faulty splicing can be corrected. Dr. Krainers research is focused in part on genes associated with spinal muscular atrophy (SMA), a neuromuscular disease that has been the leading genetic cause of death in infants. He worked on antisense approaches to correct mis-splicing, and in collaboration with Ionis Pharmaceuticals and Biogen, developed the first treatment for pediatric and adult SMA.

"I am very grateful and honored to receive this years Ross Prize," said Dr. Krainer. "My trainees and I feel privileged that our research has helped SMA patients. In keeping with the intent of this generous award, we will redouble our efforts to explore new ways to address unmet medical needs."

After a brief award presentation, a symposium will be held during which Dr. Krainer will discuss his research along with Michelle Hastings, PhD, director at Rosalind Franklin University of Medicine and Science, Edward Kaye, MD, CEO of Stoke Therapeutics, and Timothy Yu, MD, PhD, attending physician and assistant professor at Boston Childrens Hospital, who will discuss their latest research.

"Dr. Krainers remarkable discoveries have revolutionized the treatment of a devastating, crippling pediatric illness. His inventions are already giving children the ability to crawl, walk, and live their lives," said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and editor emeritus of Molecular Medicine.

Dr. Krainer and his lab have also worked to shed light on the role of splicing proteins in cancer, particularly breast cancer, and on fundamental mechanisms of splicing and its regulation.

Past recipients of the Ross Prize are: Daniel Kastner, MD, PhD, the National Institutes of Healths (NIH) National Human Genome Research Institute (NHGRI) scientific director; Huda Y. Zoghbi, MD, professor, Departments of Pediatrics, Molecular and Human Genetics, Neurology and Neuroscience at Baylor College of Medicine; Jeffrey V. Ravetch, MD, PhD, the Theresa and Eugene M. Lang Professor and head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at The Rockefeller University; Charles N. Serhan, PhD, DSc, director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Womens Hospital, the Simon Gelman Professor of Anaesthesia at Harvard Medical School and professor at Harvard School of Dental Medicine; Lewis C. Cantley, PhD, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College and New York-Presbyterian Hospital; John J. OShea, MD, scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); and Dan R. Littman, MD, PhD, the Helen L. and Martin S. Kimmel Professor of Molecular Immunology in the Skirball Institute of Biomolecular Medicine at New York University School of Medicine.

Story continues

To learn more about the Ross Prize celebration and symposium, and to register for the event, please visit http://www.nyas.org/RossPrize2020. If you would like to nominate a candidate for the 2021 Ross Prize, please make a submission here.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 2,500 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit feinstein.northwell.edu.

About Molecular Medicine

Molecular Medicine sits at the forefront of its field, rapidly disseminating discovery in the genetic, molecular, and cellular basis of physiology and disease across a broad range of specialties. With over two decades of experience publishing to a multidisciplinary audience, and continually celebrating innovation through the Ross Prize in Molecular Medicine and Anthony Cerami Award in Translational Medicine, the journal strives towards the design of better molecular tools for disease diagnosis, treatment, and prevention. Molecular Medicine is published by BMC, part of Springer/Nature, in partnership with The Feinstein Institutes for Medical Research.

About the New York Academy of Sciences

The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With more than 20,000 members in 100 countries around the world, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large. Please visit us online at http://www.nyas.org.

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL has been a National Cancer Institute designated Cancer Center since 1987. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people, including 600 scientists, students and technicians. The Meetings & Courses Program annually hosts more than 12,000 scientists. The Laboratorys education arm also includes an academic publishing house, a graduate school and the DNA Learning Center with programs for middle and high school students and teachers. For more information, visit http://www.cshl.edu

View source version on businesswire.com: https://www.businesswire.com/news/home/20200302005570/en/

Contacts

Matthew Libassi516-465-8325mlibassi@northwell.edu

Original post:
Ross Prize Awarded to Cold Spring Harbor Laboratory Professor - Yahoo Finance

Read More...

Society neglecting needs of people with rare diseases, AKU moot told – The News International

Monday, March 9th, 2020

Society neglecting needs of people with rare diseases, AKU moot told

Policymakers and stakeholders must pay greater attention to the challenges posed by rare diseases in Pakistan, said experts at a conference to mark Rare Disease Day 2020 at the Aga Khan University.

Worldwide, there are over 6,000 diseases classified as rare as they affect fewer than one in 2,000 people. In Pakistan, these diseases are not so rare because a major risk factor is prevalent: inter-family marriages which significantly raise the risk of their children suffering from genetic defects and disorders.

According to a press release issued by the AKU on Friday,

Dr Bushra Afroze, associate professor at the AKU and a clinical geneticist at the universitys teaching hospital, shared the story of Sadia Manzoor*, a girl from a small town in Sindh, to explain how the health care systems shortcomings were affecting those living with rare diseases.

Sadia was eight when the unusual symptoms started to appear. She began to lose her hair, fall over while walking, be inattentive in class and face difficulties in writing. As her problems appeared to be neurological, she was taken to a neurologist and erroneously diagnosed with a non-treatable disorder, preventing her from receiving timely treatment. When she started to experience additional symptoms such as the tendency to repeat words, she was thought to be crazy -- leading to more distress for her and her family.

Thankfully, her parents continued to feel that something was wrong and to search for help. They were finally referred to one of the countrys few genetics specialists in Karachi to learn that their daughter has remethylation defect in vitamin B12, a serious metabolic disorder. Sadia was prescribed disease-specific orphan drugs medication for a condition so rare that it is not feasible to mass produce that are very expensive. Such drugs have to be imported and are often in short supply, which in turn represents an emergency with potentially fatal consequences for Sadias family.

Sadia must have medication daily and will require continual monitoring and management of her condition. Her parents are very focused on helping her live as normal a life as possible with the result that Sadia is a happy child, attending school and enjoying her childhood.

Dr Afroze explained that providing quality care to children such as Sadia requires high-quality system-wide changes that can address several constraints: a lack of awareness; shortage of facilities, expertise and institutions as well as the geographic and economic inequities that people with rare diseases face. She quoted The Lancet Global Health Commission on High Quality Health Systems in the SDG Era 2018 report which stated that providing health services without guaranteeing a minimum level of quality was ineffective, wasteful and unethical.

Currently, there is a range of gaps in the arrangements to provide quality care for patients suffering from rare diseases. Narrowing these gaps will require collaboration between stakeholders across the spheres of research, healthcare, academia and government.

Quality is not a given, Dr Afroze said. Ensuring quality treatment for rare diseases will take vision, planning, investment, compassion, meticulous execution, and rigorous monitoring, from the national level to the smallest, remotest clinic.

As a first step, experts at the conference highlighted the importance of screening newborns for rare diseases. A simple blood test compulsory in China, Canada, the US, as well many countries in Asia and Europe can enable the prompt detection and treatment of such conditions. AKUs Professor Aysha Habib, chair of the conference, explained that tests that can screen for over 50 rare illnesses have been common in the developing world for over 50 years. In Pakistan less than one per cent of newborns are currently being screened for these diseases, since only a handful of private hospitals offer these services, and for a narrow range of just five rare diseases.

She added that more hospitals need to offer screening for rare diseases and called on the government to consider how such services could be scaled up through the public health insurance measures being introduced under the governments Ehsaas programme.

Speakers at the conference also spoke of the role of researchers in the field. At present, there are no national level studies or surveys on the prevalence of rare diseases. While there are a small number of patient registries for specific rare diseases, they exist in silos within hospitals. Data sharing between hospitals would not only enhance the accuracy of information (since a single patient travels to multiple doctors and could be recorded more than once) but would also help form a roster of patients that would enable treatment options to be explored through clinical trials. Efforts by the federal health ministry are also needed to support and streamline registries, speakers added.

Professor Habib noted that academics, clinicians and researchers need to create partnerships that would intensify the development of knowledge and skills in the field. She also highlighted the importance of patient advocacy groups in facilitating research and in fostering synergies between stakeholders.

Collaboration enables everyone to benefit from each others strengths, Professor Habib said. The challenge posed by rare diseases requires us to make the most of our existing resources while developing national and international partnerships that can meet the complex needs of those living with rare diseases that are currently being neglected.

The conference Reframe Rare in Pakistan: Breaking Silos and Bringing Synergies was preceded by two days of workshops that brought together genetic researchers, pathologists and child health specialists from public and private sector organisations across the country.

Other speakers at the event included Professor Shahid Mahmood Baig, head of Human Molecular Genetics at the National Institute for Biotechnology and Genetic Engineering and Professor Giancarlo La Marca, president of the Italian Society for Newborn Screening and Metabolic Diseases.

* The patients name has been changed to protect her identity.

View original post here:
Society neglecting needs of people with rare diseases, AKU moot told - The News International

Read More...

Page 35«..1020..34353637..40..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick